- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
EQL Pharma AB (EQL)
The EQL Pharma share price today is 20.5500, view ST EQL stock exchange data. Track the latest EQL Pharma share price with real-time updates on EQL stock performance including market cap, day range, 52-week range and dividend yield. Access EQL charts, earnings dates and analyst estimates to support your investment decisions.
Stockholm
Currency in SEK
20.5500
-0.1500(-0.72%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.1000
21.4500
52 wk Range
20.0500
98.6000
Earnings results expected in 14 days
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
20.100021.4500
52 wk Range
20.050098.6000
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
EQL Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
EQL Pharma AB Earnings Call Summary for Q2/2026
- EQL Pharma reported modest 1% sales growth in Q2 2025, with gross margin falling to 38% and EBITDA margin at 10% due to supply chain disruptions.
- The company adjusted its growth outlook to 15% for 2025-2026, expecting an EBITDA margin around 20% for the full year, with cash position at SEK 78 million.
- Strategic expansion plans include launching 100 niche products in Germany and the Netherlands by 2028-2029, with the first special generics product expected between 2026-2027.
- Melosan received approval in Turkey, with a UK launch planned through partner Medisa as part of the company's international market expansion strategy.
Last Updated: 05-11-2025, 03:18 pm
Read Full TranscriptEarnings
Latest Release
08-05-2026
EPS / Forecast
0.31 / 0.30
Revenue / Forecast
120.1M / 123.8M
Compare EQL to Peers and Sector
Metrics to compare | EQL | Sector Sector - Average of metrics from a broad group of related Consumer Non-Cyclicals sector companies | Relationship RelationshipEQLPeersSector | |
|---|---|---|---|---|
P/E Ratio | 48.4x | −0.5x | −0.3x | |
PEG Ratio | −0.68 | 0.08 | 0.00 | |
Price/Book | 2.3x | 1.3x | 2.6x | |
Price / LTM Sales | 1.4x | 0.5x | 3.0x | |
Upside (Analyst Target) | 143.3% | 25.5% | 55.4% | |
Fair Value Upside | Unlock | 26.1% | 8.8% | Unlock |
EQL Pharma AB (publ) engages in the development, marketing, and sale of generic medicines to pharmacies and hospitals in Sweden, Denmark, Norway, Finland, and the rest of Europe. It offers injection products for inpatient care and formulations for outpatient care. EQL Pharma AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the EQL Pharma (EQL) Share Price Today?
The EQL Pharma share price today is 20.5500.
What is the current EQL Pharma (EQL) share price and day range?
As of 24-07-2026, the EQL Pharma share price is 20.5500, with a previous close of 52.5000. The share price has ranged from 20.1000 to 21.4500 today, while the 52-week range spans from 20.0500 to 98.6000.
What Is the EQL Pharma Market Cap?
As of today, EQL Pharma market cap is 606.8300M.
What Is the EQL Pharma (EQL) Share Price Target?
The average 12-month share price target for EQL Pharma is 50.0000, with a high estimate of 50 and a low estimate of 50. 0 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +143.31% Upside potential.
What Is EQL Pharma's Earnings Per Share (TTM)?
The EQL Pharma EPS (TTM) is 0.4200.
When Is the Next EQL Pharma Earnings Date?
EQL Pharma will release its next earnings report on 07-08-2026.
From a Technical Analysis Perspective, Is EQL a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does EQL Pharma Trade On?
EQL Pharma is listed and trades on the Stockholm Stock Exchange.
What Is the Stock Symbol for EQL Pharma?
The stock symbol for EQL Pharma is "EQL."
How Many Times Has EQL Pharma Stock Split?
EQL Pharma has split 0 times.
How Many Employees Does EQL Pharma Have?
EQL Pharma has 60 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.